Please assess the completion status of the following clinical trial:

Trial Title: BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of B-cell leukemia or lymphoma of 1 of the following types:~  * Chronic lymphocytic leukemia~    * Failed standard chemotherapy~ * Prolymphocytic leukemia~    * Failed standard chemotherapy~ * Indolent non-Hodgkin's lymphoma, including mantle cell lymphoma~    * Stage III or IV disease~   * Failed ≥ 1 prior doxorubicin- or fludarabine-containing standard therapy~* CD22-positive disease, as evidenced by 1 of the following:~  * More than 15% malignant cells react with anti-CD22 by immunohistochemistry~ * More than 30% malignant cells are CD22-positive by fluorescence-activated cell sorting analysis~ * More than 400 CD22 sites per malignant cell (average) by radiolabeled anti-CD22 binding~* Treatment is medically indicated, as evidenced by any of the following:~  * Progressive disease-related symptoms~ * Progressive cytopenias due to marrow involvement~ * Progressive or painful splenomegaly or adenopathy~ * Rapidly increasing lymphocytosis~ * Autoimmune hemolytic anemia or thrombocytopenia~ * Increased frequency of infections~* No neutralizing anti-toxin or anti-mouse immunoglobulin G (IgG) antibodies to BL22 or PE38~  * No serum neutralization of \> 75% of the activity of 1 μg/mL of BL22~* No CNS disease requiring treatment~* No hairy cell leukemia~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* More than 6 months~Hematopoietic~* Absolute neutrophil count \> 1,000/mm\^3\*~* Platelet count \> 40,000/mm\^3 NOTE: \*Patients with leukemia are eligible regardless of absolute neutrophil count; Grade III-IV pancytopenia or growth factor dependence allowed if due to disease~Hepatic~* Bilirubin \< 1.5 times upper limit of normal (ULN)~* ALT and AST \< 2.5 times ULN~Renal~* Creatinine ≤ 1.5 mg/dL~Pulmonary~* FEV1 ≥ 60% of predicted~* DLCO ≥ 55% of predicted~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Prior bone marrow transplantation allowed~* More than 3 weeks since prior biologic therapy, including interferon, denileukin diftitox, or LMB-2 immunotoxin~* More than 3 months since prior monoclonal antibody therapy (e.g., rituximab)~Chemotherapy~* See Disease Characteristics~* More than 3 weeks since prior cytotoxic chemotherapy~Endocrine therapy~* More than 1 week since prior steriods~  * Less than 5 doses for non-treatment reasons (e.g., allergy prophylaxis)~ * No evidence of disease response~Radiotherapy~* More than 3 weeks since prior whole-body electron beam radiotherapy~  * Radiotherapy within the past 3 weeks allowed provided the volume of bone marrow treated is \< 10% AND the patient has measurable disease located outside the radiation port~Surgery~* Not specified~Other~* More than 3 weeks since prior retinoids~* More than 3 weeks since other prior systemic therapy for this malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete